$MASI (Masimo Corporation)

$MASI {{ '2016-03-01T14:04:03+0000' | timeago}} • Announcement

Monitoring technologies company $MASI said it has launched the Iris Gateway, a server-based software solution for integrating medical device data, at the HIMSS 2016 Annual Conference and Exhibition in Las Vegas. Iris Gateway helps to connect medical devices and perform the required translations to move patient data into EMRs.

$BDX {{ '2017-11-20T22:01:18+0000' | timeago}} • Announcement

$BDX has declared a quarterly dividend of $0.75 cents per common share, an increase of 2.7% from the previous quarter.  The dividend will be payable on Dec. 29, 2017 to holders of record on Dec. 8, 2017.

$ACOR {{ '2017-11-20T13:09:44+0000' | timeago}} • Announcement

$ACOR stops developing its Parkinson’s disease drug tozadenant. This decision comes a week after the drugmaker reported five deaths in key studies testing the treatment. The company would stop enrolling patients in two long-term safety trials after it found seven cases of sepsis in mid- and late-stage trials.

$LIVN {{ '2017-11-20T12:54:20+0000' | timeago}} • Announcement

$LIVN and MicroPort Scientific Corporation have entered into a binding Letter of Intent for the sale of LivaNova’s Cardiac Rhythm Management Business Franchise to MicroPort for $190MM in cash. The companies expect the transaction to close in the second quarter of 2018.

$ACOR {{ '2017-11-17T15:46:22+0000' | timeago}} • Announcement

$ACOR announced a $40MM royalty monetization with HealthCare Royalty Partners (HCR) and a $13MM royalty monetization with H. Lundbeck A/S. H. Lundbeck and $ACOR have amended the license agreement for Selincro to eliminate future royalty and milestone obligations on sales of Selincro outside of the United States.

$MMSI {{ '2017-11-16T17:40:51+0000' | timeago}} • Announcement

$MMSI signed purchase agreement with $BDX for divestment assets in connection with its proposed acquisition of $BCR$MMSI expects the acquisition to provide incremental annual revenues of $42-48MM, and adjusted gross margins for the subject product lines of 60-70%. $MMSI expects deal to provide $0.10-0.19 in adjusted EPS accretion in FY18.

$MMSI {{ '2017-11-16T17:37:46+0000' | timeago}} • Announcement

$MMSI signed an asset purchase agreement with $BDX to buy certain assets which $BDX proposes to sell in connection with its proposed acquisition of $BCR. $MMSI proposes to buy the Aspira Pleural Effusion Drainage Kits and the Aspira Peritoneal Drainage System currently marketed by $BCR. The purchase price is $100MM.

$CAH {{ '2017-11-15T12:47:08+0000' | timeago}} • Announcement

$CAH has agreed to sell its China business to Shanghai Pharmaceuticals Holding Co., Ltd. for $1.2Bil. The sale includes the company’s pharmaceutical and medical products distribution business in China. The transaction is expected to close by the end of Cardinal Health's fiscal year.

$ACOR {{ '2017-11-15T12:23:57+0000' | timeago}} • Announcement

$ACOR said it has paused new enrollment in the long-term safety studies, pending further discussion with the independent Data Safety Monitoring Board (DSMB) and the United States Food and Drug Administration (FDA).

$ACOR {{ '2017-11-15T12:23:21+0000' | timeago}} • Announcement

$ACOR lifted frequency of blood cell count monitoring for participants to weekly in Phase 3 program of tozadenant for Parkinson's disease. $ACOR took this action in response to cases of agranulocytosis, possibly drug-related, and in some cases associated with sepsis and death. Agranulocytosis is absence of white blood cells, which fight infection.

$HOLX {{ '2017-11-09T15:40:48+0000' | timeago}} • Announcement

For FY18, $HOLX expects revenue to be $3.20-3.28Bil, GAAP EPS to be $1.22-1.27 and non-GAAP EPS is estimated to be $2.10-2.15. For 1Q18, revenue is estimated to be $775-790MM, GAAP EPS to be $0.25-0.27 and non-GAAP EPS is targeted $0.48-0.50.

$HOLX {{ '2017-11-09T15:34:46+0000' | timeago}} • Announcement

$HOLX's profit dropped 10% in its final quarter of FY17 despite a 11% increase in the revenue. Net income was $83MM or $0.29 per share on revenues of $803MM. On a non-GAAP basis, Hologic earned $0.50 per share.

$MDT {{ '2017-11-09T13:05:42+0000' | timeago}} • Announcement

Preliminary 2Q18 Results: $MDT worldwide revenue declined 4% to approx. $7.05Bil, with the decline driven by the company's divestiture of its Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses to $CAH. The company expects the impact of Hurricane Maria to be approx. $0.03 to non-GAAP EPS for 2Q18.

$CAH {{ '2017-11-08T22:19:14+0000' | timeago}} • Announcement

$CAH has declared a regular quarterly dividend of $0.4624 per share on its common stock. The dividend is payable on January 15, 2018, to shareholders of record on January 2, 2018.

$HOLX {{ '2017-11-08T22:16:36+0000' | timeago}} • Infographic

$HOLX Hologic, Inc. Earnings AlphaGraphic: Q4 2017 Highlights

$REGN {{ '2017-11-08T20:41:09+0000' | timeago}} • Webcast

$REGN said Sanofi reimbursement of its commercialization-related expenses, was $90MM for 3Q17. "We are tightening and lowering our FY17 guidance of Sanofi reimbursement of Regeneron commercialization-related expenses to $350-375MM from our previous guidance range of $370-400MM," the company said.

$REGN {{ '2017-11-08T15:12:08+0000' | timeago}} • Infographic

$REGN Regeneron Pharmaceuticals, Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$REGN {{ '2017-11-08T12:35:23+0000' | timeago}} • Announcement

$REGN sees EYLEA US net sales growth of approx 10% in FY17. Meanwhile, guidance for Sanofi reimbursement has been reduced to $350-375MM, from the earlier projection of $370-400MM.

$REGN {{ '2017-11-08T12:29:30+0000' | timeago}} • Announcement

$REGN's net product sales were $957MM in 3Q17, compared to $857MM in 3Q16. EYLEA net product sales in the US were $953MM during the quarter, compared to $854MM in the year-over period.

$REGN {{ '2017-11-08T12:19:24+0000' | timeago}} • Announcement

$REGN reported double-digit growth in top and bottom-line growth in 3Q17, driven by solid sales of EYLEA injection and Praluent. Revenues improved 23% from last year to $1.5Bil, while net income rose 46% to $388MM, or $3.32 per share. On an adjusted basis, net income grew 27% to $3.99 per share.

$VRX {{ '2017-11-07T19:06:31+0000' | timeago}} • Announcement

$VRX said it will sell Sprout, the subsidiary that produces Addyi-the female libido pill, to a former shareholder of Sprout in exchange for a 6% royalty on global sales of Addyi. The sale is expected to close before the end of 2017. Addyi is the only approved and commercialized product of Sprout.

Recent Transcripts

OPK (Opko Health, Inc.)
Wednesday, November 8 2017 - 9:30pm
RMTI (Rockwell Medical, Inc.)
Wednesday, November 8 2017 - 9:30pm
HOLX (Hologic Inc.)
Wednesday, November 8 2017 - 9:30pm
ELMD (Electromed, Inc.)
Wednesday, November 8 2017 - 2:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
CAH (Cardinal Health, Inc.)
Monday, November 6 2017 - 1:30pm
XRAY (DENTSPLY International Inc.)
Friday, November 3 2017 - 12:30pm
IRIX (IRIDEX Corporation)
Thursday, November 2 2017 - 9:00pm
LIVN (LivaNova PLC)
Thursday, November 2 2017 - 1:00pm
BDX (Becton, Dickinson and Company)
Thursday, November 2 2017 - 12:00pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
AGIO (Agios Pharmaceuticals, Inc.)
Wednesday, November 1 2017 - 12:00pm
MASI (Masimo Corporation)
Tuesday, October 31 2017 - 8:30pm
ACOR (Acorda Therapeutics, Inc.)
Tuesday, October 31 2017 - 12:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, October 31 2017 - 12:30pm
OFIX (Orthofix International N.V.)
Monday, October 30 2017 - 8:30pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm

AlphaGraphics you may like